Medscape:2014年骨科医生生活方式调查报告

2014-04-24 胡添 医学界骨科频道

Medscape网站陆陆续续刊登了25个专科医生的年度生活报告,美国骨科同仁的生活状况如何?一起来看一下吧。 哪些骨科医生超重更严重呢? 2013年来自疾控中心的肥胖报告显示,男女总的肥胖流行率(35%)没有差别。 2013年盖洛普民意调查也支持这一结果。Medscape调查显示,仅8% 的男性骨科医生和3%的女性骨科医生的BMI ≥ 30 。然而,保持健康的体重对于接受调

Medscape网站陆陆续续刊登了25个专科医生的年度生活报告,美国骨科同仁的生活状况如何?一起来看一下吧。



哪些骨科医生超重更严重呢?


2013年来自疾控中心的肥胖报告显示,男女总的肥胖流行率(35%)没有差别。 2013年盖洛普民意调查也支持这一结果。Medscape调查显示,仅8% 的男性骨科医生和3%的女性骨科医生的BMI ≥ 30 。然而,保持健康的体重对于接受调查的医生们仍然是一个问题,与一般人群不同,骨科医生超重者男性(38%)比女性(25%)要多。

骨科医生选择什么样的饮食呢?

美国心脏协会/美国心脏病学心血管风险学会最新指南推荐地中海式饮食(富含水果,蔬菜,全谷类,鱼,橄榄油,瘦肉家禽,坚果,豆类)。2013年关于健康饮食的盖洛普民意调查发现,60%的美国人每周吃5份水果和四份或四份以上的,其百分比与2012年医师在盖洛普民意测验报告单一样。当Medscape调查的受访者被问及他们的饮食时,只有43%的骨科医生提及包含有日常量的水果和蔬菜的饮食。更糟的是,39%称,他们经常选择使用“meals on-the-go”(快餐食品,垃圾食品,从自动售货机餐)或典型的美国饮食(大部分时间食肉,碳水化合物大部分时间来自白米饭,土豆,或白面粉制品,高脂肪)。虽然有44%的骨科医生表示,他们介于超重与肥胖之间,只有10%的人在减肥或食用热量限制饮食。

骨科医生多久在外面点餐一次呢?
梯形论坛关于外带食品的话题指出,美国分配给外带食品的预算百分比从190年的26.3%上升到2002年的46%。大众媒体随后的报道表明,此后这一比例并没有减少。该论坛还认为,外出就餐更频繁与肥胖,较高的体内脂肪百分比,还有较高的BMI有关,其他研究也有相似的结果。但是,目前尚不能确定是外出就餐与肥胖是否存在联系,或者那些在快餐连锁店就餐的人是否更易肥胖。在Medscape调查中,65%介于超重和肥胖之间的骨科医生的说他们至少一个星期外出就餐一次。但 56%的正常和低体重者也是如此。

哪些骨科医生使用膳食补充剂?
将近一半的美国人使用某种形式的膳食补充剂。年龄和性别会影响膳食补充剂的使用。在大于46岁并参加了Medscape调查的骨科医生中,63%服用膳食补充剂,而45岁及以下的医生该比例为51%。当考虑到性别差异时,68%的女性服用补充剂,而男性为59%。有趣的是,这些结果与最近的护士健康研究(NHS)的分析和卫生专业人员随访研究(HPFS)有差别,他们报导了更高的补充剂的使用率。

骨科医生使用什么膳食补充剂呢?
约40%的骨科医生服用多种维生素,比美国一般人群的调查使用率33%要高。25%骨科医生服用omega - 3脂肪酸,27%服用维生素D,17%服用钙片。尽管补充抗氧化剂的价值缺乏证据支持,24%骨科医生服用维生素,12%服用辅酶Q10,以防止他汀类药物有关的肌痛。膳食补充剂在卫生专业人员中的使用率在1986年和2006年间有所增长,特别是在妇女服用维生素D( 2.2%至32.2%)和叶酸(0.8%至10.7%)方面。鱼油的使用在男女性中都升高(女性为1.6%至18.1%,男性为3.3%至22.2%)。另一方面,抗氧化剂维生素A , β-胡萝卜素,维生素C和维生素E的使用稳步下降。

哪些医生会休假超过4星期呢?
最近的一份涉及了21个高收入国家的报告中显示,美国是唯一一个不给员工提供带薪休假的国家。美国人每年享受平均16个带薪休假日和节假日,这比其他富裕国家的公民少(例如,意大利,新西兰,比利时有30天;法国有31天西班牙和德国有34天)。在所有医生当中,休假时间由于科室不同差别很大。骨科医生排名第六,有22%的骨科医生每年享受超过4周的假期。内分泌科医生最惨,只有11%休假超过4星期,其次是家庭医生,内科和整形外科医生,只有13%享受这么长的假期。

骨科医生做志愿者吗?

调查显示,21%的男性骨科医生,15%女性称自己从不做志愿者,这比Medscape2012年的调查数据(25%)有所降低。值得注意的是,2000年在《家庭医学档案》发表的一份调查显示,那些把慈善作为生活中指导原则的医生职业满足感更高。

骨科医生在哪里的幸福感更高
67%的骨科医生认为,在家里非常高兴。只有42%的骨科医生认为在工作中十分高兴。70%左右的皮肤科医生和眼科医生认为在家里很开心,而只有52%重症和传染病医师认为在家里很开心。皮肤科医生也是在工作中最开心的医生,有53%自称在工作中非常高兴。在工作中最不快乐的是家庭医生和急诊医生,只有36%认为自己在工作中很开心。37%的内科医生和放射科医生认为自己在工作中很开心。

骨科医生每周至少运动两次者所占百分比
2012年的盖洛普民意调查显示,54.7%的美国人,每周运动3次以上,而在同年医生的盖洛普民意测验中,58%的医生声称运动相同的次数。当根据体重来查看运动频率时,当前Medscape调查中那些正常体重的的骨科医生做得最好,其中80%的人每周至少锻炼两次。59%的超重者,56%的肥胖者声称,他们每周至少锻炼2次。

骨科医生每周喝几次酒呢?
Medscape调查显示,骨科医生并不嗜酒。男性和女性骨科医生不喝酒的比例分别为19%和25%,而53%的女性和51%的男性称他们可能一周都不喝酒。

哪些医生存款最多?
77%骨科医师声称自己有足够的储蓄,名列榜首,紧随其后的是眼科医生(76%)。只有57%的家庭医生和内科医生认为自己储蓄可观。多年来,初级保健医生和许多专家之间的收入差距一直是矛盾的焦点。《平价医疗法案》的部分修改就是为了解决这一问题,但这会起到多大的作用尚不清楚。

骨科医生婚姻状态
在过去的几十年里,美国人初婚的年龄和持续时间有很大的改变。现在,人们初婚时年纪更大,与非配偶在一起时间更长。约一半的婚姻以离婚告终。据疾控中心统计,2000年至2011年间,结婚率下降了9%,而离婚率增加了7%。骨科医生似乎在这方面做得很好。尽管女性骨科医生(77%)相比,男性骨科医生(88%) 更可能结婚或同居。

原始出处:

Carol Peckham.Medscape Orthopedist Lifestyle Report 2014.Medscape January 23, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
    2015-03-24 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
    2014-06-06 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
    2014-04-26 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1897947, encodeId=5f2d189e9475c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Mar 24 07:25:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725594, encodeId=73161e255947b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 06 01:25:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350946, encodeId=743e135094696, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458547, encodeId=e0bb145854e42, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585246, encodeId=25ba15852466f, content=<a href='/topic/show?id=e7fb101e8514' target=_blank style='color:#2F92EE;'>#骨科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101785, encryptionId=e7fb101e8514, topicName=骨科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=413917143435, createdName=lvliquan, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606168, encodeId=faf516061680e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 26 00:25:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9147, encodeId=be0f914e7c, content=我想问一下我能发文章吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbd0101519, createdName=doudou2014, createdTime=Fri Apr 25 12:03:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
    2014-04-25 doudou2014

    我想问一下我能发文章吗?

    0

相关资讯

CIT 2014:冠脉分叉病变RESOLVE评分

研究背景冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻

CIT 2014:心房颤动的卒中、出血及风险评分

心房颤动(房颤)是临床上最常见的心律失常之一。同正常人群相比,房颤具有很高的致死率和致残率,血栓栓塞并发症是其致残、致死的主要原因。非瓣膜性房颤患者的卒中风险是正常人的 5~6倍,年发生率约为5%。因此,预防卒中对房颤患者尤为重要。 口服抗凝药是目前预防房颤血栓栓塞并发症最有效的方法,调整剂量的华法林可使房颤卒中的相对危险降低68%,优于单用或双联抗血小板治疗。真实世界研究荟萃同时表明,华法林显

Medscape:2014年消化科医生生活方式调查报告

Medscape网站陆陆续续刊登了25个专科医生的年度生活报告,美国消化科同仁的生活状况如何?一起来看一下吧。 哪些消化科医生超重更严重呢? 2013年来自疾控中心的肥胖报告显示,男女总的肥胖流行率(35%)没有差别。 2013年盖洛普民意调查也支持这一结果。Medscape调查显示,仅7% 的男性消化科医生和 1%的女性消化科医生的BMI ≥

CIT 2014:TAVR发展及中国早期经验概况

自2002年法国的Cribier医生成功完成全球第一例经导管主动脉瓣置换(TAVR)术以来,该技术经过10余年的发展,目前已成为外科手术风险高或不能进行外科手术的症状性重度主动脉瓣狭窄有效的替代治疗方案。与传统的外科换瓣手术相比,TAVR具有微创(不需要开胸和体外循环)、术后恢复快等优势。PARTNER随机对照研究显示,对于无法接受外科手术的重度主动脉瓣狭窄患者,TAVR优于单纯的主动脉瓣球囊扩张

CIT 2014:SYMPLICITY HTN-3后时代,去肾神经治疗顽固性高血压路在何方?

顽固性高血压是一种特殊类型的高血压,在应用包括利尿剂在内的3种或以上的足量降压药血压仍难以达标或至少需4种降压药血压才能达标,可能导致严重的靶器官损伤和心血管风险,治疗十分棘手[1]。近年来国外已有前瞻性队列研究和随机对照研究表明[2-4],经导管射频消融肾交感神经术(renal sympathetic denervation,RDN)对于部分顽固性高血压患者具有显著持久的降压作用,且很少发生

CIT 2014:中外腹主动脉瘤流行病学特点

无论在发达国家还是发展中国家,心血管疾病都是严重威胁群众生命和健康的主要疾病,也是现代社会最主要的居民死亡原因。动脉瘤作为大血管疾病的代表性病种,其中67%为腹主动脉瘤(AAA)。 AAA具有发病隐匿和破裂致死等特征,很长一段时期以来,AAA的危害性一直为公众所忽视,多数AAA直到破裂才会被发现并开始治疗。据统计,美国10年间AAA择期手术和急诊手术的比例约为8.4 : 68。在意大利(累计11年